TRIM8 and fatty liver disease: In non-alcoholic steatohepatitis, TRIM8 ubiquitinates TAK1 inducing the phosphorylation and the activation of downstream c-Jun N-terminal kinase/p38/NF-κB pathways and promoting insulin resistance, hepatic steatosis and fibrosis in mouse livers [66].